New drug approvals for 2020: Synthesis and clinical applications

被引：42

作者：

Yuan, Shuo ^{[1
,2
]}

Luo, Yong-Qiang ^{[1
,2
]}

Zuo, Jia-Hui ^{[1
,2
]}

Liu, Hui ^{[1
,2
]}

Li, Fang ^{[1
,2
]}

Yu, Bin ^{[1
,2
]}

机构：

[1] Zhengzhou Univ, Sch Pharmaceut Sci, Zhengzhou 450001, Peoples R China

[2] Zhengzhou Univ, Key Lab Adv Drug Preparat Technol, Mil Educ, Zhengzhou 450001, Peoples R China

来源：

EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY | 2021年 / 215卷

基金：

中国国家自然科学基金;

关键词：

New drugs; Chemical synthesis; Clinical applications; FARNESYL-PROTEIN TRANSFERASE; PEPTIDE CGRP; OPEN-LABEL; PHASE-III; DISCOVERY; INHIBITORS; EFFICACY; POTENT; SELPERCATINIB; MULTICENTER;

D O I：

10.1016/j.ejmech.2021.113284

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

53 New drugs including 38 chemical entities and 15 biologics were approved by the U.S. Food and Drug Administration during 2020. Among the marketed drugs, 34 new small molecule drugs and 4 new diagnostic agents with privileged structures and novel clinical applications represent as promising leads for the development of new drugs with the similar indications and improved therapeutic efficacy. This review is mainly focused on the clinical applications and synthetic methods of 34 small-molecule drugs newly approved by the FDA in 2020. (c) 2021 Elsevier Masson SAS. All rights reserved.

引用

页数：34

共 50 条

[41] Antifungal Drug Development: Challenges, Unmet Clinical Needs, and New Approaches [J].

Roemer, Terry ;

Krysan, Damian J. .

COLD SPRING HARBOR PERSPECTIVES IN MEDICINE, 2014, 4 (05)

[42] Drug interaction networks: an introduction to translational and clinical applications [J].

Azuaje, Francisco .

CARDIOVASCULAR RESEARCH, 2013, 97 (04) :631-641

[43] New drug therapies for multiple sclerosis [J].

Mangas, Arturo ;

Covenas, Rafael ;

Geffard, Michel .

CURRENT OPINION IN NEUROLOGY, 2010, 23 (03) :287-292

[44] Precision Medicine and Immunotherapy Have Arrived for Cholangiocarcinoma: An Overview of Recent Approvals and Ongoing Clinical Trials [J].

Karasic, Thomas B. ;

Eads, Jennifer R. ;

Goyal, Lipika .

JCO PRECISION ONCOLOGY, 2023, 7

[45] Machine learning-based prediction of drug approvals using molecular, physicochemical, clinical trial, and patent-related features [J].

Ciray, Fulya ;

Dogan, Tunca .

EXPERT OPINION ON DRUG DISCOVERY, 2022, 17 (12) :1425-1441

[46] A survey of new oncology drug approvals in the USA from 2010 to 2015: a focus on optimal dose and related postmarketing activities [J].

Lu, Dan ;

Lu, Tong ;

Stroh, Mark ;

Graham, Richard A. ;

Agarwal, Priya ;

Musib, Luna ;

Li, Chi-Chung ;

Lum, Bert L. ;

Joshi, Amita .

CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2016, 77 (03) :459-476

[47] Recent applications of seven-membered rings in drug design [J].

Ouvry, Gilles .

BIOORGANIC & MEDICINAL CHEMISTRY, 2022, 57

[48] Comparison of Research Spending on New Drug Approvals by the National Institutes of Health vs the Pharmaceutical Industry, 2010-2019 [J].

Cleary, Ekaterina Galkina ;

Jackson, Matthew J. ;

Zhou, Edward W. ;

Ledley, Fred D. .

JAMA HEALTH FORUM, 2023, 4 (04) :E230511

[49] Synthesis and clinical application of new drugs approved by NMPA in 2023 [J].

Xie, Lijuan ;

Wang, Yingying ;

Wang, Kunyu ;

Chen, Wanying ;

Yang, Fuwei .

EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2025, 283

[50] Repurposing as a strategy for orphan drug development, evidence from European approvals [J].

Norman, Peter .

EXPERT OPINION ON ORPHAN DRUGS, 2013, 1 (06) :473-480

← 1 2 3 4 5 →